Deutsch English Français

Contact

EP3160504

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3160504

EP3160504 - ANTI-HISTONE THERAPY FOR VASCULAR NECROSIS IN SEVERE GLOMERULONEPHRITIS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 23.07.2021 Database last updated on 02.11.2024
Former	The patent has been granted Status updated on 14.08.2020
Former	Grant of patent is intended Status updated on 20.04.2020
Former	Examination is in progress Status updated on 20.08.2019
Former	Request for examination was made Status updated on 31.03.2017
Former	The international publication has been made Status updated on 18.01.2017
Most recent event Tooltip	06.09.2024	Lapse of the patent in a contracting state New state(s): MT	published on 09.10.2024 [2024/41]
Applicant(s)	For all designated states Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 / US
	[2017/18]
Inventor(s)	01 / KUMAR, Santhosh V. R. 300 American Road Morris Plains New Jersey 07950 / US
	02 / ANDERS, Hans-Joachim 300 American Road Morris Plains New Jersey 07950 / US
	[2017/18]
Representative(s)	Bohmann, Armin K. Bohmann Anwaltssozietät Nymphenburger Straße 1 80335 München / DE
	[2017/18]
Application number, filing date	15812106.1	23.06.2015
	[2017/18]
	WO2015US37086
Priority number, date	US201462016277P	24.06.2014 Original published format: US 201462016277 P
	[2017/18]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015200260
	Date:	30.12.2015
	Language:	EN
	[2015/52]
	Type:	A1 Application with search report
	No.:	EP3160504
	Date:	03.05.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 30.12.2015 takes the place of the publication of the European patent application.
	[2017/18]
	Type:	B1 Patent specification
	No.:	EP3160504
	Date:	16.09.2020
	Language:	EN
	[2020/38]
Search report(s)	International search report - published on:	US	30.12.2015
	(Supplementary) European search report - dispatched on:	EP	15.01.2018
Classification	IPC:	A61K38/19, A61P13/12, A61K38/20, A61K31/727, A61K38/21, A61K45/06, C07K16/18, A61K38/36, A61K39/00, A61K38/48	[2020/19]
	CPC:	C07K16/18 (EP,US); A61K31/727 (EP,US); A61K38/19 (EP,US); A61K38/191 (EP,US); A61K38/193 (EP,US); A61K38/20 (EP,US); (+) A61K38/21 (EP,US); A61K38/366 (EP,US); A61K38/4866 (EP,US); A61K39/3955 (US); A61K45/06 (EP,US); A61P13/12 (EP); C07K16/241 (US); C07K16/2896 (US); A61K2039/505 (EP,US); C07K2317/21 (US); C07K2317/24 (US); C07K2317/31 (US); C07K2317/54 (US); C07K2317/55 (US); C07K2317/569 (US); C07K2317/622 (US); C07K2317/76 (US); C07K2319/00 (US) (-)
	C-Set:	A61K38/191, A61K2300/00 (US,EP); A61K38/193, A61K2300/00 (US,EP); A61K38/19, A61K2300/00 (EP,US); A61K38/20, A61K2300/00 (US,EP); (+) A61K38/21, A61K2300/00 (EP,US); A61K38/366, A61K2300/00 (EP,US) (-)
	Former IPC [2018/07]	A61K39/395, A61K39/00, A61K36/48, A61K39/38, A61P13/12
	Former IPC [2017/18]	A61K39/395, A61K39/00, A61K36/48, A61K39/38
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/18]
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	MA	Not yet paid
Title	German:	ANTIHISTONTHERAPIE FÜR VASKULÄRE NEKROSE BEI SCHWERER GLOMERULONEPHRITIS	[2017/18]
	English:	ANTI-HISTONE THERAPY FOR VASCULAR NECROSIS IN SEVERE GLOMERULONEPHRITIS	[2017/18]
	French:	THÉRAPIE PAR ANTI-HISTONE POUR NÉCROSE VASCULAIRE DANS LA GLOMÉRULONÉPHRITE SÉVÈRE	[2017/18]
Entry into regional phase	18.01.2017	National basic fee paid
	18.01.2017	Search fee paid
	18.01.2017	Designation fee(s) paid
	18.01.2017	Examination fee paid
Examination procedure	18.01.2017	Examination requested [2017/18]
	18.01.2017	Date on which the examining division has become responsible
	13.08.2018	Amendment by applicant (claims and/or description)
	23.08.2019	Despatch of a communication from the examining division (Time limit: M04)
	02.01.2020	Reply to a communication from the examining division
	21.04.2020	Communication of intention to grant the patent
	10.08.2020	Fee for grant paid
	10.08.2020	Fee for publishing/printing paid
	10.08.2020	Receipt of the translation of the claim(s)
Opposition(s)	17.06.2021	No opposition filed within time limit [2021/34]
Fees paid	Renewal fee
	31.03.2017	Renewal fee patent year 03
	27.06.2018	Renewal fee patent year 04
	25.06.2019	Renewal fee patent year 05
	24.06.2020	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	23.06.2015
	AL	16.09.2020
	AT	16.09.2020
	CY	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	IT	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	MC	16.09.2020
	MK	16.09.2020
	MT	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
	[2024/41]
Former [2024/22]	HU	23.06.2015
	AL	16.09.2020
	AT	16.09.2020
	CY	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	IT	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	MC	16.09.2020
	MK	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2023/30]	HU	23.06.2015
	AL	16.09.2020
	AT	16.09.2020
	CY	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	IT	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	MC	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2023/28]	HU	23.06.2015
	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	IT	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	MC	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2022/08]	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	IT	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	MC	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2021/48]	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	IT	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2021/37]	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	DK	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2021/36]	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SI	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2021/28]	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SK	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2021/25]	AL	16.09.2020
	AT	16.09.2020
	CZ	16.09.2020
	EE	16.09.2020
	ES	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	PL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	IS	16.01.2021
	PT	18.01.2021
Former [2021/23]	AT	16.09.2020
	CZ	16.09.2020
	EE	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	SM	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	PT	18.01.2021
Former [2021/22]	CZ	16.09.2020
	EE	16.09.2020
	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	RO	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	PT	18.01.2021
Former [2021/21]	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
	PT	18.01.2021
Former [2021/20]	FI	16.09.2020
	HR	16.09.2020
	LT	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
Former [2021/18]	FI	16.09.2020
	HR	16.09.2020
	LV	16.09.2020
	NL	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
Former [2021/10]	FI	16.09.2020
	HR	16.09.2020
	LV	16.09.2020
	RS	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
Former [2021/09]	FI	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
	GR	17.12.2020
Former [2021/08]	FI	16.09.2020
	SE	16.09.2020
	BG	16.12.2020
	NO	16.12.2020
Former [2021/07]	FI	16.09.2020
	NO	16.12.2020
Documents cited:	Search	[Y]US5824660 (TIPPING PETER G [AU], et al) [Y] 1-15cf. abstract, claim 1;
		[Y]WO0172328 (LILLY CO ELI [US], et al) [Y] 1-15 cf. abstract, claims 1-4;
		[IP]US2014234209 (CHANG CHIEN-HSING [US], et al) [IP] 1-15 cf. abstract, claims 1, 29, 39 and 40;
		[Y] - WAKUI H ET AL, "Anti-histone autoantibodies in ddY mice, an animal model for spontaneous IgA nephritis", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, SAN DIEGO, CA, US, vol. 52, no. 2, doi:10.1016/0090-1229(89)90176-1, ISSN 0090-1229, (19890801), pages 248 - 256, (19890801), XP026187805 [Y] 1-15 cf. abstract DOI: http://dx.doi.org/10.1016/0090-1229(89)90176-1
		[Y] - AKASHI Y ET AL, "Participation of histones and ubiquitin in lupus nephritis.", NIHON JINZO GAKKAI SHI AUG 1995, (199508), vol. 37, no. 8, ISSN 0385-2385, pages 462 - 467, XP009502567 [Y] 1-15 cf. abstract, 2nd para. of the right col. at page 466
	International search	[Y]US2004126372 (BANERJEE SUBHASHIS [US], et al);
		[Y]US2006140936 (GOLDENBERG DAVID M [US], et al);
		[Y]US2009117099 (ESMON CHARLES T [US], et al);
	by applicant	US4036945
		US4331647
		US4554101
		US4671958
		US4699784
		US4704692
		US4824659
		US4925648
		US4946778
		US5057313
		WO9219273
		US5229275
		US5443953
		US5525338
		US5567610
		US5587459
		US5677136
		US5686072
		US5716595
		US5736119
		US5776456
		US5789554
		US5798229
		US5814440
		US5824660
		US5874540
		US5922302
		US6077499
		US6096289
		US6107090
		US6120767
		US6129914
		US6183744
		US6187287
		US6254868
		WO0172328
		US6306393
		US6331175
		US6340571
		US6340459
		US6344198
		US6346246
		US6355481
		US6355444
		US6355245
		US6355244
		US6359126
		US6372215
		US6376654
		US6383759
		US6383484
		US6387350
		US6395276
		US6395274
		US6403770
		US6403091
		US6406694
		US6413726
		US6419928
		US6432404
		US6432402
		US6441143
		US6444206
		US6451310
	US6455044
	US6455040
	US6458356
	US6461823
	US6465173
	US6468531
	US6468529
	US6479247
	US6482598
	US6482408
	US6488930
	US6491915
	US6511665
	US6518404
	US6521227
	US6528625
	US6528269
	US6534058
	US6545130
	US6544749
	US6562618
	US6566076
	US6572856
	US6576745
	US6592868
	US6596852
	US6605441
	US6605279
	US6610833
	US6610294
	US6630144
	US6635482
	US6645493
	US6653104
	US6652852
	US6673344
	US6676924
	US6682737
	US6682736
	US6682734
	US6689607
	US6689362
	US6689355
	US6693176
	US6692908
	US6709653
	US6716966
	US6720155
	US6730307
	US6730300
	US6733981
	US6743898
	US6764688
	US6764681
	US6764679
	US6767711
	US6770450
	US6783758
	US6793924
	US2004202666
	US6812206
	US6824780
	US6824778
	US6835549
	US6835370
	US6838282
	US6861511
	US6861227
	US6861226
	US6864062
	US6867006
	US6872568
	US6875580
	US6878812
	US6881405
	US6884594
	US6887468
	US6887466
	US6893625
	US6899879
	US6899864
	US6905681
	US6916475
	US6919433
	US6919078
	US6921645
	US6921533
	US6926893
	US6939547
	US6943020
	US6946129
	US6949244
	US6951924
	US6956107
	US6962981
	US6962813
	US6962702
	US6965018
	US6964854
	US2005271671
	US6974863
	US6989241
	US6994976
	US6994852
	US6998468
	US7001598
	US7012133
	US7038018
	US7037498
	US7041803
	US7041802
	US7041293
	US7045132
	US7049060
	US7056509
	US7060802
	US7074403
	US2006193865
	US7109304
	US7151164
	US7230084
	US7238785
	US7238786
	US7251164
	US7256004
	US7282567
	US7300655
	US7312318
	US7521056
	US7527787
	US2009117099
	US7531327
	US7534866
	US7537930
	US7541440
	US7550143
	US7563433
	US7585491
	US7608425
	US7612180
	US7642239
	US7666400
	US7785880
	US2014234209
	US8987421
	US19860616620
	US19530616735

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p